key: cord-1054446-t080tiv9 authors: Barman, Ross; Clark, Kathryn; Olatoye, Oludare title: Short-Term Lidocaine Infusion as a Non-Sedative Option to Maintain Ventilator Synchrony during Opioid Taper in a COVID-19 Patient date: 2021-10-21 journal: Pain Med DOI: 10.1093/pm/pnab311 sha: a2c9b63987676e4a3b541066092efa128d908b3a doc_id: 1054446 cord_uid: t080tiv9 nan Case Description 2 In June of 2020, a 61 year old, opioid-naïve female with no significant past medical 3 history presented to her local Emergency Department in acute hypoxic respiratory distress. She 4 was initially placed on BiPAP (100% FiO2) but was subsequently intubated due to persistent 5 hypoxia. Chest x-ray obtained in the ED revealed diffuse lung opacities suspicious for COVID-6 19 Pneumonia. She was transferred to a tertiary care ICU for advanced care measures based on 7 her presumed diagnosis, which was later confirmed to be Covid-19. In the coming days, she 8 would endure a prolonged hospitalization aggravated by complications including a type 2 non-9 ST elevation myocardial infarction (NSTEMI), renal failure necessitating continuous renal 10 replacement therapy (CRRT), and the development of opioid tolerance which eventually led to 11 an iatrogenic opioid withdrawal syndrome. When the patient was first admitted to the ICU, she was started on a continuous fentanyl 13 infusion for both sedation and analgesia. Her sources of pain included inflammation from 14 critical illness itself, endotracheal intubation, placement of multiple invasive catheters such as 15 arterial and central access lines, urinary catheter placement, three bronchoscopies, and other 16 routine procedures in the ICU. Due to concern for excess fluid intake, the patient was switched 17 from fentanyl to a more concentrated hydromorphone infusion on admission day 5. Early in her 18 hospital course she tolerated pausing opioid infusions to attempt SBTs. However, trials to assess 19 her readiness for ventilator liberation were unsuccessful and so a planned tracheostomy was 20 placed on day 31. As her hospitalization progressed, she required higher opioid doses to remain sedated. On hospitalization day 41 another sedation holiday and SBT was attempted. However, cessation 23 of the hydromorphone infusion resulted in the patient experiencing diarrhea, tachycardia, hypertension, and worsened ventilator dyssynchrony. These symptoms only resolved after 2 resuming the opioid infusion. Based on these findings, it was presumed the patient was 3 exhibiting signs of opioid withdrawal and so a gradual opioid taper was initiated. A 4 pharmacological cocktail consisting of alpha-2 agonists, antidiarrheals, and a ketamine infusion 5 (up to 1.5mg/kg/hr) was used in an attempt to manage the physiologic aberrations observed 6 during opioid weaning, yet the patient continued to grimace and show signs of agitation with 7 breakthrough hypertension, tachycardia, and ventilator dyssynchrony. The ICU team felt that the 8 patient's agitation and physiologic changes were nonspecific for either opioid withdrawal or 9 inadequate analgesia, and likely represented a contribution from both etiologies. Thus, on 10 admission day 45, the Inpatient Pain Medicine Service were consulted for further pain 11 management recommendations. At the time of this consult, the patient was on approximately 1160 OME with a ketamine 13 infusion at 1.5 mg/kg/hr ( Figure 1 ). The pain medicine team considered options such as 14 methadone, a remifentanil infusion, or a lidocaine infusion as a method to control the patient's 15 pain while tapering hydromorphone. Given that the opioid receptors were likely saturated, and 16 that the patient was already receiving an NMDA-antagonist, an alternative mechanism for non-17 sedative analgesia bypassing both pathways was deemed most appropriate. Hence, the decision 18 was made to initiate a lidocaine infusion. The lidocaine infusion was used for a total of 5 days, 19 with a rate of 1 mg/kg/hr for the first 4 days and 0.5mg/kg/hr for the final day. To avoid local 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 45-49) of continuous lidocaine infusion while drastically tapering opioids, the patient's 2 hydromorphone infusion was discontinued and she was only maintained on intermittent doses of 3 enteral hydromorphone, without signs of opioid withdrawal. Her daily OME had decreased by 4 roughly 90% from 1160 to 120 OME mg, and so the lidocaine was discontinued after a 5 day 5 infusion. Additionally, given the success of the lidocaine infusion in managing the patient's pain 6 during opioid reduction, the ketamine infusion had been discontinued on day 47. After her 7 opioid dose had been significantly reduced, she successfully tolerated daily spontaneous 8 breathing trials without further evidence of ventilator desynchrony or signs concerning for opioid 9 withdrawal. The patient transferred to an LTAC on hospital day 59 and after further convalescence, 11 she was discharged home without opioid prescriptions and has since returned to her normal state 12 of health. In the case described here, the patient is unable to communicate the subjective experience 3 of opioid withdrawal because she was intubated and mechanically ventilated. While the 4 literature suggests that the development of iatrogenic opioid withdrawal in ICU patients can be 5 anywhere from 16-30% [5] [6] [7] , it can be difficult to discern a withdrawal syndrome from the 6 natural increase in sympathetic outflow that comes with decreased sedation. Despite the inability 7 to have our patient endorse the subjective symptoms of opioid withdrawal, she did still fulfill the 8 DSM-V criteria for opioid withdrawal by having agitation, diarrhea, and a fever shortly after 9 opioid dose reduction [5] . Our diagnosis of iatrogenic opioid withdrawal was further 10 strengthened by the temporal relationship between a reduction in opioids shortly followed by the 11 patient manifesting the aforementioned symptoms. Finally, it was telling that our ICU 12 colleagues, who routinely wean patients from opioid based sedation, strongly felt that this was a 13 true opioid withdrawal presentation. 14 Our pain medicine service agreed with the ICU team that the patient was experiencing 15 opioid withdrawal; however, we were also concerned about the potential for opioid-induced 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 When the pain medicine team was consulted, the patient was being weaned from 2 hydromorphone while receiving dexmedetomidine to treat the physiologic symptoms of opioid 3 withdrawal and ketamine as a replacement analgesic. Despite high dose (1.5 mg/kg/hr) ketamine 4 infusion, our patient remained unable to tolerate opioid weaning and the ICU team expressed 5 concerns about inadequate analgesia. Thus, we recommended initiating lidocaine infusion as an 6 alternate analgesic modality. Methadone, which has been used successfully as an analgesic 7 bridge during high dose opioid taper was considered, but was avoided due to the patient's 8 tenuous cardiac status and methdone's sedative properties. The decision to utilize a lidocaine infusion to achieve analgesia while weaning opioids 10 was based on previous evidence where it has been shown to be effective as an adjunctive Answer: B Intralipid, specifically 20% Intralipid, is used as the treatment for LAST. A 1.5 10 mL/kg bolus is given initially, which is followed by an infusion at 0.25 ml/kg/min for 30-60 11 minutes. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Lidocaine Infusion as a weaning modality for Prolonged Intubation from COVID-19 Pneumonia Complicated by Iatrogenic Opioid Withdrawal Syndrome 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Clinical Practice Guidelines for the Management of Pain, Agitation Adult Patients in the Intensive Care Unit Opioid Tolerance in Critical Illness Challenges in Sedation Management in Critically Ill Patients with 9 COVID-19: a Brief Review Analgosedation: a paradigm shift in intensive care unit sedation 11 practice Opioid-associated iatrogenic withdrawal in critically ill adult patients: a 13 multicenter prospective observational study. Ann Intensive Care Iatrogenic Opioid Withdrawal Syndrome in Critically Ill Patients: a 15 Retrospective Cohort Study Acute withdrawal syndrome related to the administration of analgesic 17 and sedative medications in adult intensive care unit patients A comprehensive review of opioid-induced hyperalgesia Lidocaine Infusion: A Promising Therapeutic Approach for 22 Chronic Pain Analgesia in Intensive Care Unit Patients Lidocaine or Systemic Ketamine in Acute Pain Management of Patients With Opioid Use Disorder 27 After Orthopedic Surgery